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Abstract
Background: To evaluate the diagnostic utility of alpha-methylacyl CoA racemase (P504S) & HMWCK (34beta E12)
in morphologically difficult prostate cancer.
Methods: A total of 1034 cases were reviewed and divided into benign (585) malignant (399) and suspicious (50).
Immunohistochemistry with HMWCK and AMACR was done on the 50 suspicious cases along with controls.
Results: Forty nine suspicious cases were resolved by using both markers where as 1 case was resolved by further
support with CD68. The original diagnosis was changed in 15 of 50 (30%) suspicious cases from benign to
malignant, one case from benign to high grade PIN and in one case from malignant to benign. Change of
diagnosis was seen in 17 of 50 (34%) suspicious cases with a significant p value of 0.002. The overall diagnosis was
changed in 17 of 1034 cases (1.64%) of prostatic disease (p < 0.001).
Conclusions: A combination of HMWCK and AMACR is of great value in combating the morphologically suspicious
cases and significantly increasing the diagnostic accuracy in prostate cancer. Although, in this study the sensitivity
and specificity of HMWCK and AMACR were high, yet it should be used with caution, keeping in mind all their
pitfalls and limitations.
Introduction
The diagnosis of prostatic cancer (PC) is based on a
combination of architectural, cytological and ancillary
features rather than any single diagnostic feature none
of which is absolutely sensitive and specific. Accurate
tissue diagnosis can be very challenging due to the pre-
sence of either a small focus of cancer or due to the
presence of many benign mimickers of malignancy like
adenosis, sclerosing adenosis, atrophy, partial atrophy,
basal cell hyperplasia, clear cell cribriform hyperplasia,
post atrophic hyperplasia, nephrogenic adenoma, meso-
nephric hyperplasia, radiation atypia, seminal vesicle and
cowpers glands [1-3]. Due to the widespread use of
serum PSA as a mass screening test for prostate cancer
there has been an ever increasing number of prostate
needle biopsies and hence the need to give an accurate
diagnosis despite the limitations. Approximately 40-50%
of patients with limited cancer had moderately advanced
or advanced carcinoma on final radical prostatectomy
[4]. Therefore, underdiagnosis of a small focus of pro-
static adenocarcinoma might delay early treatment and
cause severe adverse consequences for patients. Benign
glands contain basal cells, which are absent in cancerous
glands and hence the use of basal cell markers
(HMWCK 34bE12, p63, CK5/6) to label the basal cells
when faced with an ambiguous lesion [5-7]. More
recently a positive marker for prostate carcinoma, a-
methylacyl CoA racemase (AMACR) has been reported
to have sensitivity ranging from 82-100% [8,9]. So, the
a i mo ft h i ss t u d yw a st ou s ei m m u n o h i s t o c h e m i s t r yi n
morphologically suspicious prostate and to assess how a
combination of HMWCK (34bE12) and AMACR
(p504S) contributes to a final diagnosis. In addition, the
sensitivity and specificity of HMWCK as well as
AMACR for the detection of prostate cancer and benign
prostatic tissue were also evaluated.
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In this study all prostate biopsies/transurethral resection of
prostate (TURP) specimens/prostatectomies from 2005 to
2008 were retrieved from the archives of the Dept of His-
topathology, PGIMER, Chandigarh, India. These were
1082 in number and of these 48 cases were excluded from
the study due to inadequate material or because of the
biopsy being nonrepresentative. Finally, 1034 cases were
selected for further evaluation. These included 575 needle
biopsies, 414 TURP specimens, 21 simple prostatectomies,
18 radical prostatectomies and 6 cystoprostatectomies.
The hematoxylin and eosin stained slides of all cases were
reviewed by three histopathologists and divided into 3
categories-benign (585 cases), cases with suspicious foci
(50 cases) and malignant (399 cases). The cases with suspi-
cious foci were further subjected to immunohistochemis-
try (IHC) with HMWCK (34bE12) and AMACR (p504S).
To act as control 16 cases of benign prostatic tissue
(tumorous/nontumorous) and 25 cases of frank adenocar-
cinoma of various grades were selected and subjected to
IHC with the same markers.
The 50 suspicious cases consisted of 25 needle biop-
sies, 19 TURP specimens, 4 simple prostatectomies and
2 radical prostatectomies. The age ranged from 48 to 85
years. PSA was available in 19/50 cases and ranged from
7 to 100. Of these, 30 cases were given a histopathology
report of being benign of which 14 were labeled as
benign prostatic hyperplasia (BPH), 14 as no evidence of
malignancy (NEM) and 2 as inflammation (INFL). Of
the rest, 19 cases were reported as prostatic carcinoma
(PC) and 1 case as high grade prostatic intraepithelial
neoplasia (HGPIN). These 50 suspicious cases were
further labelled into three categories (Cat). Category 1-
Initial pathology diagnosis given at the time of routine
reporting; Category 2- Reviewed (by three histopatholo-
gists) diagnosis before IHC; Category 3- Final diagnosis
after IHC with both HMWCK and AMACR. Based on
light microscopy, the 50 suspicious cases in category 2
were further classified into three subcategories A, B and
C. Category 2A was labelled as atypical small acinar
proliferations (ASAP) and consisted of 40 cases exhibit-
ing small crowded glands showing some, but not all of
the architectural and cytological features of adenocarci-
noma. These glands lacked significant cytologic abnorm-
ality, occupied < 5% of the biopsy area or raised the
possibility of one of the mimics of prostate carcinoma. In
two cases however the glands were larger but crowded.
Category 2B consisted of 7 cases of frank prostatic carci-
noma with co-existent atypical foci (PC+ATF). In 3 cases
the differential diagnosis was between cribriform PIN
and cribriform carcinoma, in 2 cases the marked focus
was suspicious for HGPIN and in 2 cases the marked
focus looked morphologically different (more benign)
from the co-existing carcinoma. These foci were picked
up for evaluation for the purpose of learning in case
such foci were encountered independently in needle
biopsies without the co-existing carcinoma. Category
2C consisted of 3 cases of camouflaged morphology
(CM)-They were camouflaged by crush artifacts and
inflammation and needed IHC for a categorical diagno-
sis. One case showed extensive crush artifact with suspi-
cious glands, the second case showed dense chronic
inflammation along with suspicious glands and the third
case showed dense lymphoplasmacytic inflammation
with atypical cells.
Immunohistochemistry for HMWCK and AMACR
The blocks from all suspicious and control cases were
cut and mounted on poly l- lysine coated glass slides.
Endogenous peroxidase activity was blocked by freshly
prepared 0.3% hydrogen peroxide in methanol for 20
minutes. Subsequently, heat-induced epitope retrieval
was performed by using citrate buffer at PH 6. IHC was
performed by using a rabbit monoclonal anti-AMACR
antibody (p504 S, clone no 13H4 1:50 dilution) and a
monoclonal anti-HMWCK antibody (clone no 34bE12
1:50 dilution).
Evaluation of immunohistochemistry: Criteria of positive/
negative staining
AMACR
Positive staining pertains to dark diffuse or granular,
cytoplasmic or luminal, but circumferential. The percen-
tage positivity was graded from 0+ to 3+ as follows:- 0%
cells (0+, negative), 1-10% cells (1+, mild), 11-50% cells
(2+, moderate), > 51% cells (3+, strong). The adjacent
benign glands should not show more than weak, partial
(noncircumferential) staining if any. Negative staining
pertains to no staining or focal, weak noncircumferential
fine granular staining.
HMWCK
The basal cell marker, HMWCK was interpreted as
negative/positive and continuous/discontinuous.
Statistical analysis
Data was analyzed using the statistical package SPSS
version 16.0 for MS-Windows (SPSS Inc., Chicago, IL).
The significance of HMWCK and AMACR immunos-
tains in resolving the atypical foci was analyzed using
chi square test. Significance was assumed at a p value
less than 0.05.
Results
Expression of HMWCK/AMACR in controls
Benign controls
In all the 16 benign controls (Table 1), HMWCK high-
lighted the presence of basal cells in the form of moder-
ate to strong cytoplasmic continuous positivity. In 14
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Page 3 of 9(87.5%) of the 16 benign controls IHC for AMACR was
totally negative. However, in 2 cases there was focal,
weak and noncircumferential luminal staining observed
in benign glands which were interpreted as negative. In
seminal vesicle (3 cases) the HMWCK stained the basal
cells and the AMACR was negative.
Malignant controls
Of the 25 cases of malignant controls (Table 2), 8 cases
had associated HGPIN in the adjacent area. In 21/25
malignant control the HMWCK was negative in the
malignant glands. However in 4 cases i.e.16% HMWCK
was strongly positive in the malignant cells/glands.
AMACR was positive in 23/25 malignant cases and
negative in two cases with the majority i.e 20/25 (80%)
showing moderate to strong positivity (Figure 1A and
1B). The location of staining was usually luminal to sub-
luminal and circumferential, but some cases showed dif-
fuse cytoplasmic staining or mixture of both pattern. All
the 8 cases with HGPIN showed strong continuous to
occasionally discontinuous positivity for HMWCK and
moderate to strong positivity for AMACR. As high-
lighted in the Table 2, two high grade (Figure 1C), one
intermediate and one low grade prostatic carcinomas
were positive for both markers. So, in this study we con-
cluded that AMACR has a sensitivity of 92% and a spe-
cificity of 100% whereas HMWCK has a sensitivity of
100% and a specificity of 84%.
Expression of HMWCK and AMACR in 50 suspicious cases
Taking into consideration the morphology, clinical
details and staining with HMWCK and AMACR the 50
suspicious cases (Table 3) were recategorized. All
ASAP’s showing moderate to strong circumferential
granular or diffuse positivity with AMACR and a nega-
tive staining with HMWCK were relabeled as adenocar-
cinoma. Those with a negative AMACR and positive
labeling with HMWCK in the basal cells as adenosis,
atrophy and those with positive labeling with HMWCK
in the luminal cells as basal cell hyperplasia. Suspicious
foci with larger glands exhibiting positive staining with
both AMACR and HMWCK as PIN. In category 2A,
14/40 ASAP cases were initially diagnosed as benign
prostatic hyperplasia (Cat 1) and of these 5 were rela-
beled (Cat 3) as carcinoma (Figure 2A and 2B), 2 as car-
cinoma with HGPIN, 3 as basal cell hyperplasia and 4 as
adenosis. Of the 14/40 ASAP cases initially diagnosed as
no evidence of malignancy (Cat 1), 5 were relabeled
(Cat 3) as carcinoma, 1 as carcinoma with HGPIN, 1
case as HGPIN, 4 as adenosis (Figure 1D) and 3 as atro-
phy. Of the 10/40 ASAP (Cat 2A) cases initially
Table 1 Expression of HMWCK/AMACR in 16 benign
controls
Antibody Benign prostates -16 Seminal
vesicle-3
HMWCK Positive-moderate to strong, cytoplasmic,
continuous
Positive
AMACR 14 cases-negative
2 cases-focal, weak, non circumferential-
Non specific
Negative
Table 2 Expression of HMWCK/AMACR in 25 malignant
controls
Antibody Low
grade-10
Intermediate-9 High-6 HGPIN-8
HMWCK 9-
negative
8-negative 4-
negative
8- Positive
1-positive 1-positive 2-
positive
Continuous/
discontinuous
AMACR 9-positive All positive 5
positive
8- positive-moderate
to strong
1-
negative
1
negative
Figure 1 A1-H&E Low grade prostate carcinoma x400.A 2 -
HMWCK negative staining in the malignant glands × 400. A3-
AMACR strong 3+ luminal circumferential positivity in the malignant
glands × 400. B1- H&E High grade prostate carcinoma × 400. B2-
HMWCK negative in the malignant cells × 400. B3- AMACR strong 3
+ positivity in the malignant cells × 400. C1-H&E High grade
prostate carcinoma × 400. C2- HMWCK strongly positive in the
malignant cells × 400. C3- AMACR strong 3+ positivity in the
malignant cells × 400. D1-H&E Focus of ASAP-adenosis × 200.
D2-HMWCK strongly positive in the basal cells × 400. D3- AMACR
shows negative staining × 400.
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Page 4 of 9diagnosed as carcinoma (Cat 1) remained so. One case
of ASAP (Cat 2A) initially diagnosed as inflammation
(Cat 1) was relabeled as carcinoma (Cat 3) and one case
initially diagnosed as HGPIN, remained so. In category
2B there were 7 cases of frank prostatic carcinoma with
atypical foci which looked different from the co-existing
carcinoma. Five atypical foci were labeled as HGPIN of
which 3 were labeled as cribriform HGPIN (Figure 2C)
and one each as adenosis and basal cell hyperplasia. In
category 2C, one case (initially reported as carcinoma)
with crush artifact showed negativity for HMWCK and
moderate positivity for AMACR hence confirming the
diagnosis of prostate carcinoma. The second case (initi-
ally reported as inflammation) with inflammation and
squamous metaplasia, the suspicious large glands
showed negative HMWCK staining and strong positivity
(3+) for AMACR, hence relabeled as carcinoma. The
third case (initially reported as malignancy) with dense
inflammation admixed with atypical cells showed nega-
tivity for AMACR. Subsequently immunostain for CD68
was performed which highlighted these atypical cells as
histiocytes giving a diagnosis of nonspecific inflamma-
tion (Figure 2D).
Change of diagnosis after immunohistochemistry-
In 17/50 i.e. 34% of the suspicious cases there was a
change of diagnosis based on morphology, clinical
details and staining with HMWCK and AMACR. In 15/
50 i.e. 30% the diagnosis was changed from benign to
malignant, in one from benign to HGPIN and in one
from malignant to benign. This change was statistically
significant with p value of < 0.002. Of the total 1034
cases, the change of diagnoses was seen in 17/1034
cases i.e 1.64%. This change in diagnosis too was statis-
tically significant with p value < 0.001. Of these 17 cases
there were 12 needle biopsies and all twelve were done
for a clinical suspicion of prostatic carcinoma. PSA
levels were available in 9/12 cases only, and were high
in all cases ranging from 7 to 100 ng/ml. Ten of these
cases had foci of ASAP which on morphology were very
suspicious. In all needle biopsies the percentage of
tumor found was 5-15% and was of Gleason score 3+3
ie 6. In 5 cases TURP was done with a clinical diagnosis
of benign prostatic hyperplasia. PSA was available in
only one case and was high (10 ng/ml). The TURP spe-
cimens revealed a very small focus of malignancy ie
3-5% with a Gleason score of 3+3 = 6. In 15 cases with
change of diagnosis from benign to malignant the
HMWCK was negative and AMACR was positive in all
cases with 2+ in 4 cases and 3+ in 11 cases.
Discussion
Prostate carcinoma is the most common form of cancer
in men and the second leading cause of death. The
advent of prostate-specific antigen screening has led to a
significant increase both in the number of prostate nee-
dle biopsies performed and in the number of difficult
biopsies with a small foci of adenocarcinoma and atypi-
cal glands suggestive but not diagnostic of adenocarci-
noma. The diagnosis of prostate cancer is made by use
of traditional histological parameters, including architec-
ture, nuclear features and ancillary features (if necessary)
r a t h e rt h a na n ys i n g l ed i a g n o s t i cf e a t u r e[ 1 ] .T i s s u e
diagnosis of prostate cancer can be difficult due to the
presence of either a small focus of cancer or due to the
many benign mimickers of malignancy like adenosis,
atrophy, partial atrophy, basal cell hyperplasia, clear cell
hyperplasia, post atrophic hyperplasia, nephrogenic ade-
noma, mesonephric hyperplasia, radiation atypia, semi-
nal vesicle and Cowpers glands [1,2]. Prostatic biopsies
occasionally contain proliferative foci of small atypical
acini that display some but not all features diagnostic of
adenocarcinoma. Such foci have been described by a wide
variety of terms which are synonymous like suspicious,
atypical focus, and atypical small acinar proliferation
Table 3 Correlation between original (Cat 1), reviewed (Cat 2) and final diagnosis (Cat 3)
Orig diag
Cat 1
Rev diag
Cat 2-A,B,C
Final diagnosis after IHC- Cat 3
PC PC+
HGPIN
PC+
ADEN
PC+BCH BCH ADEN ATROPHY HGPIN SUSP
BPH-14 ASAP-14 5 2 00 3 4 0 0 0
NEM-14 ASAP-14 5 1 00 0 4 3 1 0
INFL-2 ASAP-1 1 00 00 0 0 00
CM-1 0 1 00 0 0 0 0 0
PC-19 ASAP-10 73 0 0 00 0 0 0
CM-2 10 0 0 00 0 0 1
PC+ATF-7 05 1 1 00 0 0 0
HGPIN-1 ASAP-1 00 0 0 00 0 1 0
Cat-category, Orig-original; Rev-reviewed; diag-diagnosis, BPH- benign prostatic hyperplasia; PC-prostatic carcinoma; HGPIN- high grade prostatic intraepithelial
neoplasia; NEM-no evidence of malignancy; INFL- inflammation; BCH- basal cell hyperplasia; ADEN- adenosis; CM -camouflaged morphology; ASAP-atypical small
acinar proliferation, ATF- atypical foci, Susp- suspicious
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most accepted terminology however is ASAP. Needle
biopsies signed out as ASAP include such lesions as
HGPIN, benign mimickers of cancer (atypical adenoma-
tous hyperplasia, BCH, atrophy), reactive atypia and many
cases that in retrospect show minute carcinoma but con-
tain insufficient cytological or architectural atypia to estab-
lish a definitive diagnosis of cancer. The likelihood of
prostate cancer on subsequent biopsy in men with a diag-
nosis of ASAP on initial biopsy is 21% to 49% [10,11].
Amongst the mimickers, atrophy [2] and partial atro-
phy [12] are frequently misdiagnosed as prostate carci-
noma. Low power maintenance of lobular architecture
at least in part, uniform cytology, absence of prominent
nucleoli and presence of a basal cell layer [2] takes you
away from a diagnosis of carcinoma. Partial atrophy has
a lobular to disorganized and diffuse pattern growth
with glandular crowding which are paler and angulated
and the nuclei are occasionally larger with more promi-
nent nucleoli. The presence of patchy/absent basal cells
and pseudo nerve invasion makes it mimic an adenocar-
cinoma. Adenosis is defined as a focus of very crowded
small glands suspicious for cancer, admixed with more
recognizably benign glands. Glands have pale to clear
cytoplasm with nuclei showing a lack of a very promi-
nent nucleoli [13,14] and possess a fragmented or con-
tinuous basal cell layer [2]. Basal cell hyperplasia is a
mimicker of prostate carcinoma especially in needle
biopsies. It is usually characterized by a nodular expan-
sion of uniform round glands associated with a cellular
stroma. Morphologically there are residual small lumina
lined by secretary cells with clear cytoplasm and these
are surrounded by multiple layers of basal cells which
are dark with a scant cytoplasm and a round or oval
spindled hyperchromatic nuclei [2] and which stain with
the basal cell markers. Nephrogenic adenoma is a
benign metaplastic response of the urothelium to injury
and can rarely affect the prostatic urethra. Extension of
small tubules of nephrogenic adenoma into the underly-
ing prostatic fibromuscular stroma can lead to a mis-
diagnosis of low grade prostatic adenocarcinoma.
Presence of Cowpers glands in TURP specimens may
resemble both low grade adenocarcinoma or foamy
gland carcinoma both of which can have a bland cytol-
ogy. Occasionally seminal vesicles sampled on needle
biopsy can also be a source of over diagnosing prostatic
adenocarcinoma. A common finding on needle biopsy is
the dilated irregular lumen of the seminal vesicle seen at
the edge of the tissue core with surrounding clusters of
small glands.
In recent years basal cell markers and prostate bio-
marker Alpha-Methylacyl- CoA- Racemase (AMACR)
have been used as adjuvant to morphology in diagnosti-
cally challenging cases with a very high sensitivity and
specificity. This has increased the diagnostic accuracy of
prostate cancer worldwide. Basal cell markers such as
HMWCK (34bE12) and CK 5/6 and P63 are very useful
for demonstration of basal cells as their presence argues
against a diagnosis of invasive prostatic carcinoma [7].
There are several caveats associated with the use of
basal cell markers for the diagnosis of PC. The first is
that one is relying on a negative finding ie lack of basal
cell staining to make a positive diagnosis of carcinoma.
The second caveat is that 5% to 23% of benign prostatic
gland [8,14], up to 50% of cases of adenosis in a frag-
mented pattern with some totally negative glands [15],
23% cases of atrophy [16], 44%-75% cases of nephro-
genic adenoma [17] and 66% cases of mesonephric
hyperplasia may lack basal cell staining and thus a nega-
tive basal cell marker immunostain alone does not lead
us towards a diagnosis of malignancy. Seminal vesicle
Figure 2 A1-H&E ASAP focus in NBX-PC × 400.A 2 -H M W C K
shows negative staining × 400. A3-AMACR strong 3+ luminal
circumferential positivity × 400. B1-H&E ASAP focus in TURP- PC ×
400. B2- HMWCK negative staining × 400. B3-AMACR strong 3+
luminal circumferential positivity × 400. C1-H&E Atypical focus-
HGPIN × 400. C2- HMWCK strongly positive in the basal cells × 400.
C3- AMACR strong 3+ positivity in the cells × 400. D1-H&E
Camouflouged morphology- Inflammation × 400. D2-AMACR
negative staining in the atypical cells × 400. D3- CD 68 strong
positivity in the atypical cells × 400.
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Page 6 of 9and ejaculatory duct epithelium is usually positive for
basal cell markers where as data regarding Cowper’s
g l a n d si sc o n t r a d i c t o r y[ 1 8 ] .H e n c e ,o n em u s tb ec a u -
tious in interpreting negative basal immunostains as
they are supportive of a diagnosis of PC in the appropri-
ate H&E context. The final caveat is the fact that there
are reports of PC positive for basal cell markers [14,19].
Most of these positive cases are high grade PC’s and are
usually readily diagnosed based on H&E appearance.
But there are reports of gland forming invasive acinar
adenocarcinomas reported to harbor basal cells in 1% of
cases [19]. Some of these could represent carcinoma
outpouchings from HGPIN glands or alternatively flat
HGPIN. Thus, although basal cell markers are an extre-
mely useful adjunct, it is important to recognize that the
diagnosis of cancer is based on the absence of a detect-
able positive basal cell layer. Therefore, a sensitive and
specific positive immunohistochemical marker is neces-
sary to increase the level of confidence in establishing a
definitive diagnosis of malignancy in prostate pathology.
AMACR also known as racemase or p504 S is an
enzyme recently identified by cDNA subtraction and
microarray technology. It is a sensitive and specific IHC
marker found to be consistently up regulated in prostate
carcinoma [20]. A notable advantage to an AMACR
immunostain is that a diagnosis of malignancy is substan-
tiated by a positive signal rather than loss of a signal.
Multiple studies have now evaluated the utility of
AMACR immunostain in the diagnosis of PC. But there
are varied reports regarding the expression of AMACR
in prostate cancer which ranges from 62% to 100%
[8,9,20-24]. Some morphological variants of prostatic car-
cinoma that pose a particular diagnostic problem and for
which immunohistochemistryi sp a r t i c u l a r l yn e e d e dt o
establish the diagnosis of malignancy have been reported
to express less AMACR immunoreactivity compared
with their more conventional counterparts. Zhou et al
[22] found AMACR expression in 70-77% of pseudohy-
perpalstic carcinomas and 62-68% of foamy gland
cancers. In addition to prostate cancer, AMACR positiv-
ity has been demonstrated in 90% cases of HGPIN sug-
gesting that the possibility of HGPIN must be carefully
excluded by morphology and the use of basal cell mar-
kers, before AMACR positivity is used to establish the
diagnosis of adenocarcinoma. AMACR positivity in
HGPIN has been found to vary from weak to strong.
AMACR expression is also identified in 4%-21% of
benign prostatic glands [20,21] in up to 18- 27% of cases
of adenosis [25] and in 18-58% of cases of nephrogenic
adenoma [26,27]. Although AMACR is a useful immuno-
histochemical marker for prostate cancer, it has signifi-
cant limitations. It is so emphasized that AMACR should
be interpreted in the appropriate morphological context
and in conjunction with basal cell markers.
On reviewing 1034 prostate cases, 50 ie 4.8% atypical
cases were deleniated. These were divided into three
categories (40 cases of ASAP, 7 cases of prostate cancer
with atypical foci and 3 cases of camouflaged morphol-
ogy) and subjected to further analysis by immunohisto-
chemistry with HMWCK and AMACR. In various
studies in literature the incidence of atypical biopsies
ranged from 0.4-23% with a mean of 5.5% [28]. In the
index study based on morphology, clinical details and
the interpretation of the two markers we were able to
resolve 49 of the 50 atypical cases (98%) and by addition
of CD68 immunostain the remaining case was also
resolved. Jiang et al [29] found that the AMACR and
HMWCK (34bE12) immunohistochemistry in the
workup of 41 foci of so-called atypical small acinar pro-
liferation (ASAP) led to a 76% agreement rate between
the 3 pathologists participating in the study. Zhou et al
[22] demonstrated that, of 115 prostate biopsies diag-
nosed as atypical by an expert pathologist, 34 (30%)
were changed to a final diagnosis of cancer based on a
positive AMACR immunostain. Browne et al [30] also
found that the use of a cocktail of both a basal cell anti-
body and an AMACR immunostain helped resolve the
diagnosis in 70% (86/123) of ‘’challenging’’ prostate nee-
dle biopsies. Sanderson et al [31] used p63/AMACR
cocktail to reclassify 2 (29%) of 7 atypical prostate nee-
dle biopsies as prostatic carcinoma. Molinie et al [32]
were able to resolve 89% of 104 “ASAP” in needle biop-
sies using a p63/AMACR antibody cocktail compared
with only 53% with CK 5/6. Kunju et al [23] were able
t or e s o l v e2 7( 9 3 % )o f2 9a t y p i cal biopsies after immu-
nostaining with AMACR and basal cell markers.
In the present study, taking into consideration the
morphology, clinical details and in conjunction with
IHC with HMWCK and AMACR, 24/40 ASAP (Cat 2A)
cases with a negative staining with HMWCK and mod-
erate to strong positive staining with AMACR were
finally categorized as prostatic carcinoma of which only
10 were initially (Cat1) reported as carcinoma. Two
cases showing strong positive staining for AMACR and
also strongly highlighting the basal cell layer with
34bE12 were diagnosed as HGPIN (Cat 1- one reported
as HGPIN and one as NEM), In conjunction with mor-
phology, a negative AMACR stain and a positive basal
cell layer with 34bE12, 8 cases were labeled as adenosis
(Cat 1 reported as BPH and NEM), 3 as basal cell
hyperplasia (Cat 1 reported as BPH) and 3 cases as atro-
phy one of which being partial atrophy (Cat 1 reported
as NEM). These 14 cases finally labeled as adenosis,
atrophy and basal cell hyperplasia were however strongly
positive for 34bE12 and negative for AMACR and none
of these were interpreted as PC initially (Cat 1). Hence
in the ASAP category 2A there was a change in diagno-
sis in 15 of the 40 cases. In 14 cases it was from benign
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HGPIN. There were 7 cases of frank PC with atypical
foci. These foci were picked up for evaluation for the
purpose of learning in case such foci were encountered
independently in needle biopsies without the carcinoma.
Of these 5/7 were finally categorized as HGPIN and one
case each as adenosis and basal cell hyperplasia. Three
cases initially labeled as cribriform carcinoma was now
labeled as cribriform PIN and this brought down the
grade of the tumor from intermediate to low grade. The
last category was labeled as camouflaged morphology (3
cases) in which there was inflammation and crush arti-
facts. These were finally categorized as PC in 2 cases
(Cat 1-one case reported as inflammation and other as
PC) and histiocyte rich inflammation in one case (Cat 1
reported as PC). Thus in this study the initial diagnosis
made on routine reporting was changed in 17/50 ie in
34% of the atypical cases. In 15/50 i.e. 30% the diagnosis
was changed from benign to malignant, in 2% (1/50)
from benign to HGPIN and in 2% (1/50) from malig-
nant to benign. The change of diagnosis in these 17
patients was communicated to the treating urologists for
further follow up and action. The case in which the
diagnosis was changed from malignant to benign, in the
mean time had had a radical prostatectomy done and
there was dense inflammation and no tumor in the
whole specimen. Another case where the diagnosis was
changed from benign to malignant on a needle biopsy
underwent a radical prostatectomy and there was tumor
(Gleason score 3+3 = 6) present in both the lobes.
The most common reason for the diagnostic error in
this study was that the malignant foci were very limited
(3-10%) and there are well known reasons for the diffi-
culty in diagnosing limited prostatic adenocarcinoma.
Firstly the limited number of cancerous glands may only
be a few acini available for histopathological evaluation.
AMACR has now been demonstrated to be a highly sen-
sitive prostatic cancer marker (sensitivity 80-100%) for
small focal prostatic carcinomas [32-34]. Secondly there
is no single feature specific and sufficient for the diagno-
sis of prostate cancer. The diagnosis is based on a com-
bination of architectural and cytological features and the
presence of extracellular material such as blue tinged
secretions or crystalloids
,. Almost any of these histologi-
cal diagnostic features can be occasionally seen in
benign conditions of the prostate [11]. Thirdly, the con-
sequences associated with a false positive or negative
diagnosis can be very serious like unnecessary prosta-
tectomy, radiation exposure or a delay in effective treat-
ment. In this study 94% cases with change of diagnosis
were from benign to malignant/premalignant that is
cases were being underdiagnosed at our institute due to
the presence of limited adenocarcinoma. It would be
better if the diagnosis of suspicious but not diagnostic
of malignancy is given to such cases. The other reasons
for the error were inflammation, crush artifacts, missing
out on HGPIN (not looking at high power judiciously),
and diagnostic errors with benign mimics of carcinoma.
In the five TURP specimens the single chip with the
small focus of carcinoma was missed on routine report-
ing. In one case the only chip with carcinoma was lying
outside the cover slip- a technical error.
Among the control cases AMACR was positive in 23/
25 PC and negative in 14/16 benign controls with focal
weak noncircumferential positivity in 2 cases (considered
as negative). HMWCK was positive in all 16 benign con-
trols and in 4/24 PC cases. So, in this study we concluded
that AMACR has a sensitivity of 92% and a specificity of
100% whereas HMWCK has a sensitivity of 100% and a
specificity of 84%. Four cases of malignant controls (two
high grade, one intermediate grade and one low grade)
had positivity for both HMWCK and AMACR immunos-
taining. Rarely high grade prostate carcinomas can
express HMWCK and this is usually not a diagnostic
problem as AMACR is positive in the malignant cells (as
was in our cases) and morphology is diagnostic of malig-
nancy [7]. Most of the positive cases reported in litera-
ture [14] are high grade PC’s but there are reports of
gland forming invasive acinar adenocarcinomas reported
to harbor basal cells in 1% of cases [19]. Staining in a
basal cell pattern can be explained by the possibility of
retention of basal cells by early invasive carcinoma or
that some glands seem to be outpouchings of HGPIN or
alternatively flat HGPIN. This false positive staining is
seen more with HMWCK than with p63. Some antigen
retrieval methods have been implicated in nonspecific
staining of prostate cancer cells by basal cell markers
[29,35]. It was noted that the hot plate antigen retrieval
method though better for the overall staining, caused
nonspecific immunoreactivity in the tumor cells. The
pepsin predigestion and microwave retrieval methods did
not cause this phenomenon, however some benign acinar
basal cells failed to stain with these methods.
So, we conclude that in conjunction with morphology
and clinical scenario, a combination of HMWCK and
AMACR is of great value in combating the morphologi-
cally suspicious cases and thus significantly increasing
the diagnostic accuracy in prostate cancer. However, the
limitations of both the markers should be kept in mind.
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